Use of organo-silane compound (e.g. monomethylsilanetriol salicylate) in the manufacture of preparations targeted to constrain the organization of protein fibers and glycoproteins of extra-cellular matrix of injured conjunctive tissues

摘要

Use of at least one organo-silane compound (I) for the manufacture of a pharmaceutical preparation targeted to constrain the organization of protein fibers and glycoproteins of the extra-cellular matrix of injured conjunctive tissues. Use of at least one organo-silane compound (I) of formula: (R x-Si(OH) 4 -x) for the manufacture of preparation (especially pharmaceutical preparation), containing supra-physiological doses of (I), targeted to constrain the organization of protein fibers and glycoproteins of the extra-cellular matrix of injured conjunctive tissues; where (I) is stabilized by the formation of weak or strong bonds with an organic carrier (alcohol, phenol, acid, amine and/or amino acid). R : 1-4C alkyl, 2-5C alkenyl or aryl; and x : 1-3. ACTIVITY : Ophthalmological; Dermatological; Vulnerary. The effect of monomethylsilanetriol salicylate to treat wrinkles and cutaneous depression was tested in humans. The administration of monomethylsilanetriol salicylate provided amelioration of relief from the conditions in 40% of the patients after 3 months of treatment. MECHANISM OF ACTION : Collagenase inhibitor; Elastase inhibitor; Glucuronidase inhibitor.